**SUPPLEMENTARY APPENDIX**

**Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin’s lymphoma**

Beatriz Sánchez-Espiridión,§ Ana M. Martin-Moreno,¹ Carlos Montalbán,² L. Jeffrey Medeiros,³ Francisco Vega,³ Anas Younes,⁴ Miguel A. Piris,⁵ and Juan F. Garcia¹

¹Department of Pathology, M.D. Anderson Cancer Center, Houston, TX, USA; ²Department of Internal Medicine, Hospital Ramón y Cajal, Madrid Spain; ³Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; ⁴Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; and ⁵Hospital Marques de Valdecilla, IFIMAV, Santander, Spain


---

**Online Supplementary Figure S1.** Comparison between quantification of CD68 IHC-positivity (PGM1 clone) by an automated scanning system, versus “manual” scoring of an experienced hematopathologists. (Spearman’s coefficient=0.432; P<0.001)
Online Supplementary Figure S2. Kaplan-Meier Plots for disease specific survival analyses (DSS) from the different immunohistochemical markers included in the study. Most survival analyses were not significant with the different cut-off points used. For graphical representation, only median and 5% cut-off points were selected. ns: not significant.
CD68 (KP1 Clone)

CD163
Online Supplementary Figure S3. Kaplan-Meier Plots for overall survival (OS) from the different immunohistochemical markers included in the study. Most survival analyses were not significant with the different cut-off points used. For graphical representation, only median and 5% cut-off points were selected.